Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 639 Intra-tumor delivery of IF...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
639 Intra-tumor delivery of IFN-alpha by Tie-2 transduced monocytes associated with favorable 2-year survival in unmethylated MGMT GBM patients: preliminary results of TEM-GBM phase 1/2a study

639 Intra-tumor delivery of IFN-alpha by Tie-2 transduced monocytes associated with favorable 2-year survival in unmethylated MGMT GBM patients: preliminary results of TEM-GBM phase 1/2a study

Bibliographic Details
Main Authors: Fabio Ciceri, Alessandro Olivi, Valeria Ferla, PAOLO FERROLI, Francesca Farina, Carlo Russo, Bernhard Gentner, Marica Eoli, Elena Anghileri, Matteo Barcella, Valentina Brambilla, Matteo Carrabba, Valeria Cuccarini, Giorgio D’Alessandris, Francesco Di Meco, Filippo Gagliardi, Federico Legnani, Stefania Mazzoleni, Roberto Pallini, Marco Saini, Silvia Snider, Karen Mullen, Luigi Naldini, Gaetano Finocchiaro
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • P1359: USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY)
    by: F. Farina, et al.
    Published: (2022-06-01)
  • Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report
    by: Chengcheng Guo, et al.
    Published: (2019-01-01)
  • Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps
    by: Valeria Cuccarini, et al.
    Published: (2024-04-01)
  • MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma
    by: Hong Shik Yun, et al.
    Published: (2024-05-01)
  • Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines.
    by: Zev A Binder, et al.
    Published: (2016-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs